Novartis shares: remibrutinib Phase III win; YTB323 halt
Novartis reported mixed clinical outcomes: remibrutinib met Phase III relapsing MS endpoints for a planned MSTORONTO2026 presentation. The firm paused YTB323 after patient deaths and saw a failed cardiovascular Phase III.
Novartis AG (SIX:NOVN) reported mixed results, saying remibrutinib met Phase III relapsing MS endpoints and will be presented at MSTORONTO2026. The company also said it paused YTB323 after patient deaths and disclosed a failed cardiovascular Phase III study. Separately, Novartis licensed Hybrozyme and plans Basel site changes.